The U.S. Market for Intranasal Drug Delivery is Projected to Reach US$7.3 Billion by 2022

Expanding Applications in Neurology & Ongoing R&D Initiatives Spur Growth in the Intranasal Drug Delivery Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Intranasal Drug Delivery market. The U.S. market for Intranasal Drug Delivery is projected to reach US$7.3 billion by 2022, driven by the growing prevalence of major respiratory diseases and neurological disorders and ongoing R&D of delivery technologies.

Intranasal drug delivery, a highly effective method involving the administration of drugs through the nasal cavity, is gaining prominence for its effectiveness in the treatment of a growing range of chronic and acute conditions, including allergic infections, analgesics, osteoporosis to pain management, anxiety, depression, and sexual dysfunction. Researchers and drug developers are developing novel drug delivery technologies that enhance patient outcomes by offering greater therapeutic benefits and by encouraging higher patient compliance. A growing range of local anesthetics, antibiotics, antihistamines, bronchodilators, calcium, corticosteroids, decongestant sprays, pain relief drugs, snuffs, supplements, vasoconstrictors and other drugs are administered through the intranasal route in the form of ointments, sprays, powders, gels, and drops. Increasing R&D is unlocking more therapeutic areas for nasal drug delivery, including pain, diabetes mellitus, Attention Deficit Hyperactivity Disorder (ADHD), opioid overdose, Gastroparesis, migraine, and Social Anxiety Disorder (SAD).

The primary factor driving growth in the market is the growing incidence of diseases such as allergic rhinitis and neurological disorders like Alzheimer’s disease and depression. The popularity and universal acceptance of intranasal drug administration by doctors and researchers alike is largely due to the technique’s efficiency and ease in delivering systemic drugs. This is of special significance, given the emergence and popularity of self-administration of drugs for personal management and control of chronic conditions. The rapidly aging population is lending momentum to the development of intranasal drugs and drug-delivery devices that are minimally invasive and disruptive to the quality of life of patients. The increasing focus on pediatric intranasal drugs is another key force multiplier for the market. A number of high-margin blockbuster drugs continue to fall off the patent cliff, giving way to cheaper generics, and severely denting revenue lows of pharma majors. The mounting pressure on pharmaceutical companies to shorten the cycle and cost of drug development is bringing about a sea-change in drug development processes and strategies. Against this backdrop, non-traditional drug delivery routes, such as nasal application and oral inhalation, offer a unique value proposition for drug developers to launch new products and meet the growing demand among patients for minimally invasive, portable, convenient and homecare-friendly therapeutics.

As stated by the new market research report on Intranasal Drug Delivery, Allergic Infections represent the largest therapeutic area for Intranasal Drug Delivery in the United States. Analgesics ranks as the fastest-growing market with a CAGR of 15.8% over the analysis period.

Major players covered in the report include Aegis Therapeutics LLC, Alza Corporation, AstraZeneca PLC, Becton Dickinson and Company, GlaxoSmithKline PLC, Johnson & Johnson, Inc., Marina Biotech, Inc., MedImmune Inc., Merck & Co., Nemera, Novartis AG, OptiNose AS, Pfizer Inc., and Valeant Pharmaceuticals International Inc.

The research report titled “Intranasal Drug Delivery: A US Market Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies.  The report provides market estimates and projections for the US market for the following  Therapeutic Areas, namely Allergic Infections, Analgesics, Osteoporosis, and Vaccinations.

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.